oncology venture is a drug development company formed in 2012 dedicated to unlock the potential of new oncology products, and rescue failed drugs. our method improves the efficacy of the drugs, increase the response rate in cancer patients, reduce timelines and improve success rates in oncology drug development.
Company profile
Ticker
ALLR
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Allarity Therapeutics Europe ApS • Allarity Therapeutics Denmark ApS ...
ALLR stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
26 Mar 24
S-8
Registration of securities for employees
25 Mar 24
8-K
Entry into a Material Definitive Agreement
19 Mar 24
424B5
Prospectus supplement for primary offering
19 Mar 24
8-K
Entry into a Material Definitive Agreement
15 Mar 24
8-K
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
8 Mar 24
10-K
2023 FY
Annual report
8 Mar 24
DEF 14A
Definitive proxy
7 Mar 24
8-K
Departure of Directors or Certain Officers
4 Mar 24
8-K
Entry into a Material Definitive Agreement
1 Mar 24
Latest ownership filings
SC 13G/A
3i, LP
12 Feb 24
3
Laura Benjamin
28 Aug 23
3
Joseph Walter Vazzano
2 Aug 23
SC 13G
INTRACOASTAL CAPITAL, LLC
14 Jul 23
SC 13G
INTRACOASTAL CAPITAL, LLC
28 Apr 23
SC 13G/A
Forsakringsaktiebolaget Avanza Pension
10 Mar 23
SC 13G
3i, LP
2 Mar 23
SC 13G/A
Forsakringsaktiebolaget Avanza Pension
26 Jan 23
SC 13G/A
Forsakringsaktiebolaget Avanza Pension
25 Jan 23
SC 13G/A
Forsakringsaktiebolaget Avanza Pension
24 Jan 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.40 mm | 1.40 mm | 1.40 mm | 1.40 mm | 1.40 mm | 1.40 mm |
Cash burn (monthly) | (no burn) | 212.25 k | 1.48 mm | 1.58 mm | 1.79 mm | 1.13 mm |
Cash used (since last report) | n/a | 1.26 mm | 8.77 mm | 9.41 mm | 10.65 mm | 6.70 mm |
Cash remaining | n/a | 137.11 k | -7.37 mm | -8.01 mm | -9.25 mm | -5.30 mm |
Runway (months of cash) | n/a | 0.6 | -5.0 | -5.1 | -5.2 | -4.7 |
Institutional ownership, Q2 2023
94.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 1 |
Closed positions | 2 |
Increased positions | 2 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 33.82 mm |
Total shares | 5.83 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
3i | 2.99 mm | $0.00 |
Forsakringsaktiebolaget Avanza Pension | 1.37 mm | $259.00 k |
& Larsen ApS Sass | 1.06 mm | $0.00 |
Intracoastal Capital | 400.00 k | $262.00 k |
UBS UBS Group AG - Registered Shares | 3.62 k | $23.87 mm |
Tower Research Capital | 1.43 k | $9.43 mm |
Acadian Asset Management | 32.00 | $0.00 |
Proequities | 0.00 | $0.00 |
Press releases
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
27 Mar 24
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
25 Mar 24
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
8 Mar 24
Allarity Therapeutics to Present at Biomarkers 2024
28 Feb 24